Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes

Conclusion Patients gained vision (mean of 21 letters at 12 months) and showed reduced CST. These results support the continued use of ranibizumab in the treatment of iCNV. Trial registration number 2008-007476-19, results.
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Original articles - Clinical science Source Type: research